ASX · OVN.AX
Oventus Medical Limited
A$0.02A$0.00 (0.0%)
Oventus Medical Limited’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
Loading market information…
ASX · UBI.AX · AUD
Stock price, earnings
Quote as of Feb 12, 2026, 05:25 PM UTC. Cached market data; not a live quote.
One-year closing-price history · AUD. Historical prices are not a forecast.
Universal Biosensors, Inc.’s quoted price sits in the lower half of its reported 52-week range, 91.25% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Universal Biosensors, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Established in 2001 and headquartered in Rowville, Australia, Universal Biosensors, Inc., through its subsidiary Universal Biosensors Pty Ltd, operates as a specialized biosensor technology company. Its core business involves the creation, production, and market introduction of point-of-use devices designed to measure analytes across diverse industries. Within the medical field, the company manufactures and provides Prothrombin Time International Normalized Ratio coagulation test strips, and also acts as a distributor for Siemens' Xprecia Stride Coagulation Analyzer, which is crucial for monitoring individuals undergoing warfarin anticoagulant treatment. For the winemaking sector, UBI produces and distributes Sentia SO2 test strips and supplies the Sentia Analyzer, essential for determining free sulfur dioxide levels in post-fermentation wine. Additionally, the company offers non-diagnostic laboratory services and conducts specific coagulation testing. A key collaboration includes a licensing agreement with LifeScan Global Corporation to develop a biosensor strip and an accompanying meter for detecting and managing diabetes in animals.
Latest available per-share figures in AUD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 06:11 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
A$0.02A$0.00 (0.0%)
Oventus Medical Limited’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
A$0.00A$0.00 (0.0%)
Analytica Limited’s quoted price sits in the lower half of its reported 52-week range, 50.0% below the high.
A$0.00-A$0.00 (-50.0%)
Medibio Limited’s quoted price sits in the lower half of its reported 52-week range, 50.0% below the high.
A$0.02A$0.00 (0.0%)
Bod Science Limited’s quoted price sits in the lower half of its reported 52-week range, 11.11% below the high.
A$0.04A$0.00 (0.0%)
Freedom Care Group Holdings Ltd.’s quoted price sits in the lower half of its reported 52-week range, 82.38% below the high.
A$0.00A$0.00 (0.0%)
Stemcell United Limited’s quoted price sits in the lower half of its reported 52-week range, 78.57% below the high.
A$0.07A$0.00 (0.0%)
Visioneering Technologies, Inc.’s quoted price sits in the lower half of its reported 52-week range, 73.6% below the high.
A$0.01+A$0.00 (+33.33%)
Regeneus Ltd’s quoted price sits in the upper half of its reported 52-week range, 40.0% below the high.
